{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/lithium",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982234",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982234_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"St John's wort\" outputclass=\"int-drug\">St John's wort</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  St John's wort  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "189",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982235",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982235_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">Aceclofenac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Aceclofenac   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aceclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982236",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982236_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"acetazolamide\" outputclass=\"int-drug\">Acetazolamide</ph> <ph outputclass=\"int-effect\">alters</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Acetazolamide   alters   the concentration of   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acetazolamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982237",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982237_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"almotriptan\" outputclass=\"int-drug\">almotriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  almotriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Almotriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982238",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982238_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"amifampridine\" outputclass=\"int-drug\">amifampridine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  amifampridine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amifampridine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982239",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982239_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"aminophylline\" outputclass=\"int-drug\">Aminophylline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Aminophylline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982239_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"aminophylline\" outputclass=\"int-drug\">Aminophylline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Aminophylline   is predicted to   decrease   the concentration of   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aminophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982240",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982240_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"amiodarone\" outputclass=\"int-drug\">amiodarone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  amiodarone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiodarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982241",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982241_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"amisulpride\" outputclass=\"int-drug\">amisulpride</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  amisulpride  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amisulpride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982242",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982242_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">Amitriptyline</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Amitriptyline   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amitriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982243",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982243_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"amphotericin B\" outputclass=\"int-drug\">Amphotericin B</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Amphotericin B   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amphotericin B</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982244",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982244_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  anagrelide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982245",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982245_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">apalutamide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  apalutamide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982246",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982246_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"apomorphine\" outputclass=\"int-drug\">apomorphine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  apomorphine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apomorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982247",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982247_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"arsenic trioxide\" outputclass=\"int-drug\">arsenic trioxide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  arsenic trioxide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Arsenic trioxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982248",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982248_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"artemether\" outputclass=\"int-drug\">artemether</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  artemether  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Artemether</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982249",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982249_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"artenimol\" outputclass=\"int-drug\">artenimol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  artenimol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Artenimol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982250",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982250_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"azilsartan\" outputclass=\"int-drug\">Azilsartan</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor concentration and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Azilsartan   potentially   increases   the concentration of   lithium .  Manufacturer advises monitor concentration and adjust dose .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azilsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982251",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982251_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bambuterol\" outputclass=\"int-drug\">Bambuterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bambuterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bambuterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982252",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982252_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"beclometasone\" outputclass=\"int-drug\">Beclometasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Beclometasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Beclometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982253",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982253_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"bedaquiline\" outputclass=\"int-drug\">bedaquiline</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  bedaquiline  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bedaquiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982254",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982254_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">Bendroflumethiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bendroflumethiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982254_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">Bendroflumethiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose and monitor concentration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Bendroflumethiazide   increases   the concentration of   lithium .  Manufacturer advises avoid or adjust dose and monitor concentration .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982255",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982255_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"benzydamine\" outputclass=\"int-drug\">Benzydamine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Benzydamine   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Benzydamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982256",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982256_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"betamethasone\" outputclass=\"int-drug\">Betamethasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Betamethasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982257",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982257_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  bosutinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982258",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982258_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bromfenac\" outputclass=\"int-drug\">Bromfenac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bromfenac   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bromfenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982259",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982259_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"budesonide\" outputclass=\"int-drug\">Budesonide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Budesonide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Budesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982260",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982260_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">Bumetanide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bumetanide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982260_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">Bumetanide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Bumetanide   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982261",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982261_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bupropion\" outputclass=\"int-drug\">Bupropion</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">enhance</ph> <ph outputclass=\"int-parameter\">the risk of serotonin syndrome when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">MHRA advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bupropion   might   enhance   the risk of serotonin syndrome when given with   lithium .  MHRA advises monitor .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bupropion</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982262",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982262_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  cabozantinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982263",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982263_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"calcitonins\" outputclass=\"int-drug\">Calcitonins</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Calcitonins   decrease   the concentration of   lithium .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcitonins</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982264",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982264_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"candesartan\" outputclass=\"int-drug\">Candesartan</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor concentration and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Candesartan   potentially   increases   the concentration of   lithium .  Manufacturer advises monitor concentration and adjust dose .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Candesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982265",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982265_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"captopril\" outputclass=\"int-drug\">Captopril</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Captopril   is predicted to   increase   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Captopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982266",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982266_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   increase   the risk of neurotoxicity when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982267",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982267_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982268",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982268_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">ceritinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  ceritinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982269",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982269_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">Chlorothiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chlorothiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982269_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">Chlorothiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose and monitor concentration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Chlorothiazide   increases   the concentration of   lithium .  Manufacturer advises avoid or adjust dose and monitor concentration .    \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982270",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982270_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  chlorpromazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982270_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">Chlorpromazine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises discontinue if neurotoxicity develops</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Chlorpromazine   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises discontinue if neurotoxicity develops .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorpromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982271",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982271_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">Chlortalidone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose and monitor concentration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chlortalidone   increases   the concentration of   lithium .  Manufacturer advises avoid or adjust dose and monitor concentration .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982271_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">Chlortalidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Chlortalidone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982272",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982272_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  citalopram  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982272_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  lithium  and  citalopram  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982273",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982273_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">clarithromycin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  clarithromycin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982274",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982274_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  clomipramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982274_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  lithium  and  clomipramine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982274_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">Clomipramine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Clomipramine   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982275",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982275_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"crizotinib\" outputclass=\"int-drug\">crizotinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  crizotinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crizotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982276",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982276_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  dapoxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982277",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982277_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  dasatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982278",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982278_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deflazacort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982279",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982279_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"delamanid\" outputclass=\"int-drug\">delamanid</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  delamanid  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Delamanid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982280",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982280_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"demeclocycline\" outputclass=\"int-drug\">Demeclocycline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of lithium (<ph otherprops=\"lithium carbonate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/lithium-carbonate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP2337\">lithium carbonate</xref></ph>, <ph otherprops=\"lithium citrate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/lithium-citrate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP2344\">lithium citrate</xref></ph>) toxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Demeclocycline   is predicted to   increase   the risk of lithium ( lithium carbonate ,  lithium citrate ) toxicity when given with   lithium .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Demeclocycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982281",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982281_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"desflurane\" outputclass=\"int-drug\">desflurane</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  desflurane  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982282",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982282_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dexamethasone\" outputclass=\"int-drug\">Dexamethasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dexamethasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982283",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982283_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"dexamfetamine\" outputclass=\"int-drug\">dexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  dexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982284",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982284_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">Dexketoprofen</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dexketoprofen   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982285",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982285_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">Diclofenac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Diclofenac   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982286",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982286_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"diltiazem\" outputclass=\"int-drug\">Diltiazem</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Diltiazem   is predicted to   increase   the risk of neurotoxicity when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diltiazem</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982287",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982287_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"disopyramide\" outputclass=\"int-drug\">disopyramide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  disopyramide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Disopyramide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982288",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982288_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"domperidone\" outputclass=\"int-drug\">Domperidone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Domperidone   increases   the risk of QT-prolongation when given with   lithium .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Domperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982289",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982289_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dosulepin\" outputclass=\"int-drug\">Dosulepin</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dosulepin   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dosulepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982290",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982290_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"doxepin\" outputclass=\"int-drug\">Doxepin</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Doxepin   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982291",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982291_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"doxycycline\" outputclass=\"int-drug\">Doxycycline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of lithium (<ph otherprops=\"lithium carbonate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/lithium-carbonate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP2337\">lithium carbonate</xref></ph>, <ph otherprops=\"lithium citrate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/lithium-citrate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP2344\">lithium citrate</xref></ph>) toxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Doxycycline   is predicted to   increase   the risk of lithium ( lithium carbonate ,  lithium citrate ) toxicity when given with   lithium .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxycycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982292",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982292_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">dronedarone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  dronedarone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982293",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982293_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"droperidol\" outputclass=\"int-drug\">droperidol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  droperidol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Droperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982294",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982294_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  duloxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982295",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982295_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">efavirenz</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  efavirenz  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Efavirenz</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982296",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982296_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"eletriptan\" outputclass=\"int-drug\">eletriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  eletriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eletriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982297",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982297_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enalapril\" outputclass=\"int-drug\">Enalapril</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Enalapril   is predicted to   increase   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enalapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982298",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982298_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"encorafenib\" outputclass=\"int-drug\">encorafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  encorafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Encorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982299",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982299_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"entrectinib\" outputclass=\"int-drug\">entrectinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  entrectinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Entrectinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982300",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982300_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">Eplerenone</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eplerenone   potentially   increases   the concentration of   lithium .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eplerenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982301",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982301_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eprosartan\" outputclass=\"int-drug\">Eprosartan</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor concentration and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eprosartan   potentially   increases   the concentration of   lithium .  Manufacturer advises monitor concentration and adjust dose .    \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eprosartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982302",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982302_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"eribulin\" outputclass=\"int-drug\">eribulin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  eribulin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eribulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982303",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982303_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">erythromycin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  erythromycin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erythromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982304",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982304_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  escitalopram  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982304_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  lithium  and  escitalopram  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982305",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982305_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etodolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982306",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982306_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">Etoricoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etoricoxib   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoricoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982307",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982307_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"felbinac\" outputclass=\"int-drug\">Felbinac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Felbinac   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Felbinac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982308",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982308_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"fenfluramine\" outputclass=\"int-drug\">fenfluramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  fenfluramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fenfluramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982309",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982309_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"fentanyl\" outputclass=\"int-drug\">fentanyl</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  fentanyl  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fentanyl</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982310",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982310_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fingolimod\" outputclass=\"int-drug\">Fingolimod</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fingolimod   might   increase   the risk of QT-prolongation when given with   lithium .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fingolimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982311",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982311_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"flecainide\" outputclass=\"int-drug\">flecainide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  flecainide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flecainide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982312",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982312_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">fluconazole</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  fluconazole  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982313",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982313_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fludrocortisone\" outputclass=\"int-drug\">Fludrocortisone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fludrocortisone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982314",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982314_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  fluoxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982315",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982315_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">Flurbiprofen</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Flurbiprofen   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flurbiprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982316",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982316_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  fluvoxamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982317",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982317_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"formoterol\" outputclass=\"int-drug\">Formoterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Formoterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Formoterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982318",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982318_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosinopril\" outputclass=\"int-drug\">Fosinopril</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosinopril   is predicted to   increase   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982319",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982319_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"frovatriptan\" outputclass=\"int-drug\">frovatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  frovatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Frovatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982320",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982320_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"furosemide\" outputclass=\"int-drug\">Furosemide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Furosemide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982320_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"furosemide\" outputclass=\"int-drug\">Furosemide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Furosemide   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982321",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982321_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"glasdegib\" outputclass=\"int-drug\">glasdegib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  glasdegib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glasdegib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982322",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982322_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"granisetron\" outputclass=\"int-drug\">granisetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  granisetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982322_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"granisetron\" outputclass=\"int-drug\">Granisetron</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Granisetron   is predicted to   increase   the risk of QT-prolongation when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Granisetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982323",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982323_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  haloperidol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Haloperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982324",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982324_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">Hydrochlorothiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydrochlorothiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982324_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">Hydrochlorothiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose and monitor concentration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Hydrochlorothiazide   increases   the concentration of   lithium .  Manufacturer advises avoid or adjust dose and monitor concentration .    \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982325",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982325_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrocortisone\" outputclass=\"int-drug\">Hydrocortisone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydrocortisone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982326",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982326_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">Hydroflumethiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydroflumethiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982326_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">Hydroflumethiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose and monitor concentration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Hydroflumethiazide   increases   the concentration of   lithium .  Manufacturer advises avoid or adjust dose and monitor concentration .    \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982327",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982327_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"hydroxychloroquine\" outputclass=\"int-drug\">hydroxychloroquine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  hydroxychloroquine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxychloroquine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982328",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982328_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"hydroxyzine\" outputclass=\"int-drug\">hydroxyzine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  hydroxyzine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxyzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982329",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982329_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">Ibuprofen</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ibuprofen   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982330",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982330_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"imidapril\" outputclass=\"int-drug\">Imidapril</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Imidapril   is predicted to   increase   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imidapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982331",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982331_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  imipramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982331_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"imipramine\" outputclass=\"int-drug\">Imipramine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Imipramine   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982332",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982332_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indacaterol\" outputclass=\"int-drug\">Indacaterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indacaterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indacaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982333",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982333_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indapamide\" outputclass=\"int-drug\">Indapamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indapamide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982333_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indapamide\" outputclass=\"int-drug\">Indapamide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose and monitor concentration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Indapamide   increases   the concentration of   lithium .  Manufacturer advises avoid or adjust dose and monitor concentration .    \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982334",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982334_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indometacin\" outputclass=\"int-drug\">Indometacin</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indometacin   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indometacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982335",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982335_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"inotuzumab ozogamicin\" outputclass=\"int-drug\">inotuzumab ozogamicin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  inotuzumab ozogamicin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotuzumab ozogamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982336",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982336_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"irbesartan\" outputclass=\"int-drug\">Irbesartan</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor concentration and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Irbesartan   potentially   increases   the concentration of   lithium .  Manufacturer advises monitor concentration and adjust dose .    \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irbesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982337",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982337_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"isocarboxazid\" outputclass=\"int-drug\">isocarboxazid</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  isocarboxazid  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isocarboxazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982338",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982338_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"isoflurane\" outputclass=\"int-drug\">isoflurane</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  isoflurane  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isoflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982339",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982339_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ivabradine\" outputclass=\"int-drug\">Ivabradine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of torsade de pointes when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ivabradine   is predicted to   increase   the risk of torsade de pointes when given with   lithium .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ivabradine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982340",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982340_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">Ketoprofen</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketoprofen   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982341",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982341_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">Ketorolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketorolac   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketorolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982342",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982342_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"lapatinib\" outputclass=\"int-drug\">lapatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  lapatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lapatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982343",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982343_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"lenvatinib\" outputclass=\"int-drug\">lenvatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  lenvatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenvatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982344",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982344_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  levomepromazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982344_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">Levomepromazine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises discontinue if neurotoxicity develops</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Levomepromazine   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises discontinue if neurotoxicity develops .    \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levomepromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982345",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982345_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"linezolid\" outputclass=\"int-drug\">linezolid</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  linezolid  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Linezolid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982346",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982346_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"lisdexamfetamine\" outputclass=\"int-drug\">lisdexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  lisdexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisdexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982347",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982347_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lisinopril\" outputclass=\"int-drug\">Lisinopril</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lisinopril   is predicted to   increase   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982348",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982348_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lofepramine\" outputclass=\"int-drug\">Lofepramine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lofepramine   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lofepramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982349",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982349_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"lofexidine\" outputclass=\"int-drug\">lofexidine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  lofexidine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lofexidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982350",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982350_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"losartan\" outputclass=\"int-drug\">Losartan</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor concentration and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Losartan   potentially   increases   the concentration of   lithium .  Manufacturer advises monitor concentration and adjust dose .    \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Losartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982351",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982351_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lymecycline\" outputclass=\"int-drug\">Lymecycline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of lithium (<ph otherprops=\"lithium carbonate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/lithium-carbonate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP2337\">lithium carbonate</xref></ph>, <ph otherprops=\"lithium citrate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/lithium-citrate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP2344\">lithium citrate</xref></ph>) toxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lymecycline   is predicted to   increase   the risk of lithium ( lithium carbonate ,  lithium citrate ) toxicity when given with   lithium .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lymecycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982352",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982352_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">Mefenamic acid</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mefenamic acid   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982353",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982353_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mefloquine\" outputclass=\"int-drug\">Mefloquine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mefloquine   is predicted to   increase   the risk of QT-prolongation when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefloquine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982354",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982354_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meloxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982355",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982355_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  methadone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982355_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  lithium  and  methadone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methadone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982356",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982356_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"methyldopa\" outputclass=\"int-drug\">Methyldopa</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Methyldopa   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methyldopa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982357",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982357_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"methylprednisolone\" outputclass=\"int-drug\">Methylprednisolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Methylprednisolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylprednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982358",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982358_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"methylthioninium chloride\" outputclass=\"int-drug\">methylthioninium chloride</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  methylthioninium chloride  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylthioninium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982359",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982359_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"metolazone\" outputclass=\"int-drug\">Metolazone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose and monitor concentration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Metolazone   increases   the concentration of   lithium .  Manufacturer advises avoid or adjust dose and monitor concentration .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982359_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"metolazone\" outputclass=\"int-drug\">Metolazone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Metolazone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982360",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982360_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"metronidazole\" outputclass=\"int-drug\">Metronidazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Metronidazole   is predicted to   increase   the concentration of   lithium .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metronidazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982361",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982361_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Unknown\" outputclass=\"int-message\">\n  <ph otherprops=\"mexiletine\" outputclass=\"int-drug\">Mexiletine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">affects</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Unknown",
							"hasOrder": "1",
							"hasTextContent": "Mexiletine   potentially   affects   the exposure to   lithium .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mexiletine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982362",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982362_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"minocycline\" outputclass=\"int-drug\">Minocycline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of lithium (<ph otherprops=\"lithium carbonate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/lithium-carbonate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP2337\">lithium carbonate</xref></ph>, <ph otherprops=\"lithium citrate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/lithium-citrate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP2344\">lithium citrate</xref></ph>) toxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Minocycline   is predicted to   increase   the risk of lithium ( lithium carbonate ,  lithium citrate ) toxicity when given with   lithium .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Minocycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982363",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982363_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"mirtazapine\" outputclass=\"int-drug\">mirtazapine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  mirtazapine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mirtazapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982364",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982364_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mizolastine\" outputclass=\"int-drug\">Mizolastine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mizolastine   is predicted to   increase   the risk of QT-prolongation when given with   lithium .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mizolastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982365",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982365_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"moclobemide\" outputclass=\"int-drug\">moclobemide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  moclobemide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moclobemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982366",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982366_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"moxifloxacin\" outputclass=\"int-drug\">moxifloxacin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  moxifloxacin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxifloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982367",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982367_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">Nabumetone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nabumetone   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nabumetone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982368",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982368_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"naproxen\" outputclass=\"int-drug\">Naproxen</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Naproxen   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naproxen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982369",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982369_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"naratriptan\" outputclass=\"int-drug\">naratriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  naratriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naratriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982370",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982370_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nepafenac\" outputclass=\"int-drug\">Nepafenac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nepafenac   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nepafenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982371",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982371_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">nilotinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  nilotinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982372",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982372_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">Nortriptyline</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nortriptyline   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nortriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982373",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982373_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"olmesartan\" outputclass=\"int-drug\">Olmesartan</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor concentration and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Olmesartan   potentially   increases   the concentration of   lithium .  Manufacturer advises monitor concentration and adjust dose .    \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olmesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982374",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982374_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"olodaterol\" outputclass=\"int-drug\">Olodaterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Olodaterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olodaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982375",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982375_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"ondansetron\" outputclass=\"int-drug\">ondansetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  ondansetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982375_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"ondansetron\" outputclass=\"int-drug\">ondansetron</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  lithium  and  ondansetron  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ondansetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982376",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982376_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"osilodrostat\" outputclass=\"int-drug\">osilodrostat</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  osilodrostat  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Osilodrostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982377",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982377_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"osimertinib\" outputclass=\"int-drug\">osimertinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  osimertinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Osimertinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982378",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982378_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"oxcarbazepine\" outputclass=\"int-drug\">Oxcarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oxcarbazepine   is predicted to   increase   the risk of neurotoxicity when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxcarbazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982379",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982379_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"oxytetracycline\" outputclass=\"int-drug\">Oxytetracycline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of lithium (<ph otherprops=\"lithium carbonate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/lithium-carbonate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP2337\">lithium carbonate</xref></ph>, <ph otherprops=\"lithium citrate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/lithium-citrate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP2344\">lithium citrate</xref></ph>) toxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oxytetracycline   is predicted to   increase   the risk of lithium ( lithium carbonate ,  lithium citrate ) toxicity when given with   lithium .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxytetracycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982380",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982380_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ozanimod\" outputclass=\"int-drug\">Ozanimod</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ozanimod   might   increase   the risk of QT-prolongation when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ozanimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982381",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982381_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"paliperidone\" outputclass=\"int-drug\">paliperidone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  paliperidone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paliperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982382",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982382_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"palonosetron\" outputclass=\"int-drug\">palonosetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  palonosetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982382_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"palonosetron\" outputclass=\"int-drug\">Palonosetron</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Palonosetron   is predicted to   increase   the risk of QT-prolongation when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Palonosetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982383",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982383_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"panobinostat\" outputclass=\"int-drug\">panobinostat</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  panobinostat  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Panobinostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982384",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982384_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">Parecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Parecoxib   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Parecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982385",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982385_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  paroxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982386",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982386_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"pasireotide\" outputclass=\"int-drug\">pasireotide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  pasireotide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pasireotide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982387",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982387_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  pazopanib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982388",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982388_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Intravenous</ph> <ph otherprops=\"pentamidine\" outputclass=\"int-drug\">pentamidine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Intravenous   pentamidine   potentially   increases   the risk of QT-prolongation when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentamidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982389",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982389_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"pentazocine\" outputclass=\"int-drug\">pentazocine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  pentazocine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentazocine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982390",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982390_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"pericyazine\" outputclass=\"int-drug\">Pericyazine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises discontinue if neurotoxicity develops</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Pericyazine   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises discontinue if neurotoxicity develops .    \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pericyazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982391",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982391_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"perindopril\" outputclass=\"int-drug\">Perindopril</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Perindopril   is predicted to   increase   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perindopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982392",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982392_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"pethidine\" outputclass=\"int-drug\">pethidine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  pethidine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pethidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982393",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982393_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenazone\" outputclass=\"int-drug\">Phenazone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenazone   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982394",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982394_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"phenelzine\" outputclass=\"int-drug\">phenelzine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  phenelzine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenelzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982395",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982395_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  pimozide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pimozide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982396",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982396_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">Piroxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Piroxicam   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Piroxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982397",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982397_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ponesimod\" outputclass=\"int-drug\">Ponesimod</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ponesimod   might   increase   the risk of QT-prolongation when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ponesimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982398",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982398_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"prednisolone\" outputclass=\"int-drug\">Prednisolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Prednisolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982399",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982399_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"prochlorperazine\" outputclass=\"int-drug\">Prochlorperazine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises discontinue if neurotoxicity develops</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Prochlorperazine   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises discontinue if neurotoxicity develops .    \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prochlorperazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982400",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982400_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"promazine\" outputclass=\"int-drug\">Promazine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises discontinue if neurotoxicity develops</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Promazine   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises discontinue if neurotoxicity develops .    \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Promazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982401",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982401_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"quetiapine\" outputclass=\"int-drug\">Quetiapine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises discontinue if neurotoxicity develops</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Quetiapine   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises discontinue if neurotoxicity develops .    \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quetiapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982402",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982402_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"quinapril\" outputclass=\"int-drug\">Quinapril</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Quinapril   is predicted to   increase   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982403",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982403_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"quinine\" outputclass=\"int-drug\">quinine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  quinine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982404",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982404_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ramipril\" outputclass=\"int-drug\">Ramipril</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ramipril   is predicted to   increase   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramipril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982405",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982405_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"ranolazine\" outputclass=\"int-drug\">ranolazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  ranolazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ranolazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982406",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982406_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"rasagiline\" outputclass=\"int-drug\">rasagiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  rasagiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rasagiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982407",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982407_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"ribociclib\" outputclass=\"int-drug\">ribociclib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  ribociclib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ribociclib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982408",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982408_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"risperidone\" outputclass=\"int-drug\">risperidone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  risperidone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982408_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"risperidone\" outputclass=\"int-drug\">Risperidone</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises discontinue if neurotoxicity develops</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Risperidone   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises discontinue if neurotoxicity develops .    \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Risperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982409",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982409_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"rizatriptan\" outputclass=\"int-drug\">rizatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  rizatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rizatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982410",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982410_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"safinamide\" outputclass=\"int-drug\">safinamide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  safinamide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Safinamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982411",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982411_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"salbutamol\" outputclass=\"int-drug\">Salbutamol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Salbutamol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salbutamol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982412",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982412_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"salmeterol\" outputclass=\"int-drug\">Salmeterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Salmeterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salmeterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982413",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982413_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"selegiline\" outputclass=\"int-drug\">selegiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  selegiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selegiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982414",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982414_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"selpercatinib\" outputclass=\"int-drug\">selpercatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  selpercatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "180",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selpercatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982415",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982415_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  sertraline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "181",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sertraline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982416",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982416_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"sevoflurane\" outputclass=\"int-drug\">sevoflurane</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  sevoflurane  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "182",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sevoflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982417",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982417_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"sildenafil\" outputclass=\"int-drug\">sildenafil</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  sildenafil  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "183",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sildenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982418",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982418_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"siponimod\" outputclass=\"int-drug\">Siponimod</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Siponimod   might   increase   the risk of QT-prolongation when given with   lithium .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "184",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Siponimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982419",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982419_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-drug\">Sodium bicarbonate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Sodium bicarbonate   decreases   the concentration of   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "185",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium bicarbonate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982420",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982420_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  sorafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "186",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982421",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982421_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"sotalol\" outputclass=\"int-drug\">sotalol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  sotalol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "187",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sotalol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982422",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982422_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">Spironolactone</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Spironolactone   potentially   increases   the concentration of   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "188",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Spironolactone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982423",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982423_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"sulindac\" outputclass=\"int-drug\">Sulindac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Sulindac   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "190",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulindac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982424",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982424_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"sulpiride\" outputclass=\"int-drug\">sulpiride</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  sulpiride  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982424_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"sulpiride\" outputclass=\"int-drug\">Sulpiride</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises discontinue if neurotoxicity develops</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Sulpiride   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises discontinue if neurotoxicity develops .    \n\n"
						}
					],
					"hasOrder": "191",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulpiride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982425",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982425_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"sumatriptan\" outputclass=\"int-drug\">sumatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  sumatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "192",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sumatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982426",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982426_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  sunitinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "193",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982427",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982427_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tapentadol\" outputclass=\"int-drug\">Tapentadol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of serotonin syndrome when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tapentadol   is predicted to   increase   the risk of serotonin syndrome when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "194",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tapentadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982428",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982428_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"telmisartan\" outputclass=\"int-drug\">Telmisartan</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor concentration and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Telmisartan   potentially   increases   the concentration of   lithium .  Manufacturer advises monitor concentration and adjust dose .    \n\n"
						}
					],
					"hasOrder": "195",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telmisartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982429",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982429_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">Tenoxicam</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tenoxicam   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "196",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenoxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982430",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982430_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"terbutaline\" outputclass=\"int-drug\">Terbutaline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Terbutaline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "197",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terbutaline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982431",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982431_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"tetrabenazine\" outputclass=\"int-drug\">tetrabenazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  tetrabenazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "198",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tetrabenazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982432",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982432_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tetracycline\" outputclass=\"int-drug\">Tetracycline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of lithium (<ph otherprops=\"lithium carbonate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/lithium-carbonate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP2337\">lithium carbonate</xref></ph>, <ph otherprops=\"lithium citrate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/lithium-citrate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP2344\">lithium citrate</xref></ph>) toxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tetracycline   is predicted to   increase   the risk of lithium ( lithium carbonate ,  lithium citrate ) toxicity when given with   lithium .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "199",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tetracycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982433",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982433_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"theophylline\" outputclass=\"int-drug\">Theophylline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Theophylline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982433_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"theophylline\" outputclass=\"int-drug\">Theophylline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor concentration and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Theophylline   is predicted to   decrease   the concentration of   lithium .  Manufacturer advises monitor concentration and adjust dose .    \n\n"
						}
					],
					"hasOrder": "200",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Theophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982434",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982434_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">Tiaprofenic acid</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tiaprofenic acid   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "201",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tiaprofenic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982435",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982435_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"tizanidine\" outputclass=\"int-drug\">tizanidine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  tizanidine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "202",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tizanidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982436",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982436_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">Tolfenamic acid</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tolfenamic acid   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "203",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolfenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982437",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982437_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"tolterodine\" outputclass=\"int-drug\">tolterodine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  tolterodine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "204",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolterodine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982438",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982438_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"torasemide\" outputclass=\"int-drug\">Torasemide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Torasemide   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982438_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"torasemide\" outputclass=\"int-drug\">Torasemide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Torasemide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "205",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982439",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982439_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"toremifene\" outputclass=\"int-drug\">toremifene</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  toremifene  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "206",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Toremifene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982440",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982440_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"tramadol\" outputclass=\"int-drug\">tramadol</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  tramadol  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "207",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tramadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982441",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982441_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"trandolapril\" outputclass=\"int-drug\">Trandolapril</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Trandolapril   is predicted to   increase   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "208",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trandolapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982442",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982442_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"tranylcypromine\" outputclass=\"int-drug\">tranylcypromine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  tranylcypromine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "209",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tranylcypromine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982443",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982443_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"trazodone\" outputclass=\"int-drug\">trazodone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  trazodone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "210",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trazodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982444",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982444_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"triamcinolone\" outputclass=\"int-drug\">Triamcinolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Triamcinolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "211",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamcinolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982445",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982445_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"triamterene\" outputclass=\"int-drug\">Triamterene</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the clearance of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Triamterene   potentially   increases   the clearance of   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "212",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamterene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982446",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982446_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"trifluoperazine\" outputclass=\"int-drug\">Trifluoperazine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises discontinue if neurotoxicity develops</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Trifluoperazine   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises discontinue if neurotoxicity develops .    \n\n"
						}
					],
					"hasOrder": "213",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trifluoperazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982447",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982447_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"trimipramine\" outputclass=\"int-drug\">Trimipramine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Trimipramine   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "214",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982448",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982448_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"tryptophan\" outputclass=\"int-drug\">tryptophan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  tryptophan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "215",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tryptophan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982449",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982449_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"valsartan\" outputclass=\"int-drug\">Valsartan</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor concentration and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Valsartan   potentially   increases   the concentration of   lithium .  Manufacturer advises monitor concentration and adjust dose .    \n\n"
						}
					],
					"hasOrder": "216",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982450",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982450_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"vandetanib\" outputclass=\"int-drug\">vandetanib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  vandetanib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "217",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vandetanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982451",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982451_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"vardenafil\" outputclass=\"int-drug\">vardenafil</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  vardenafil  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "218",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vardenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982452",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982452_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"vemurafenib\" outputclass=\"int-drug\">vemurafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  vemurafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "219",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vemurafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982453",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982453_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  venlafaxine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982453_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  lithium  and  venlafaxine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "220",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982454",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982454_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"verapamil\" outputclass=\"int-drug\">Verapamil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Verapamil   is predicted to   increase   the risk of neurotoxicity when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "221",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Verapamil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982455",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982455_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"vernakalant\" outputclass=\"int-drug\">vernakalant</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  vernakalant  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "222",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vernakalant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982456",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982456_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"vilanterol\" outputclass=\"int-drug\">Vilanterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Vilanterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "223",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vilanterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982457",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982457_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  vinflunine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "224",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinflunine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982458",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982458_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">voriconazole</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  voriconazole  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "225",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982459",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982459_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  vortioxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "226",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vortioxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982460",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982460_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"xipamide\" outputclass=\"int-drug\">Xipamide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose and monitor concentration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Xipamide   increases   the concentration of   lithium .  Manufacturer advises avoid or adjust dose and monitor concentration .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982460_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"xipamide\" outputclass=\"int-drug\">Xipamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Xipamide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "227",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982461",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982461_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"zolmitriptan\" outputclass=\"int-drug\">zolmitriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  zolmitriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "228",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zolmitriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982462",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982462_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph> and <ph otherprops=\"zuclopenthixol\" outputclass=\"int-drug\">zuclopenthixol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  lithium  and  zuclopenthixol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/lithium#bnf_i1643857982462_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"zuclopenthixol\" outputclass=\"int-drug\">Zuclopenthixol</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-heading-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises discontinue if neurotoxicity develops</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Zuclopenthixol   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises discontinue if neurotoxicity develops .    \n\n"
						}
					],
					"hasOrder": "229",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zuclopenthixol</title>"
					}
				}
			],
			"hasSearchLabel": " Lithium  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/lithium.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Lithium </title>"
			},
			"rdfs:label": "lithium"
		}
	]
}